Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice

https://doi.org/10.1016/S0091-3057(02)00845-6Get rights and content

Abstract

It has been suggested that metabotropic glutamate (mGlu) receptor agonists selective for Group II mGlu receptors may have antipsychotic action. Therefore, we studied whether the effects, which could be related to psychotomimetic action of hallucinogenic drugs, are inhibited by Group II mGlu receptor agonists. The selective mGlu2/3 agonists LY354740 and LY379268 inhibited (±)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head twitches in mice in a dose-dependent manner. Furthermore, LY379268 suppressed an increase in the frequency of spontaneous excitatory synaptic potentials induced by bath-applied DOI in layer V pyramidal cells recorded in the murine medial frontal cortex. The data indicate that Group II mGlu receptor agonists may counteract the effects of hallucinogenic drugs.

Introduction

It has been postulated that brain 5-HT2A receptors may be involved in the pathogenesis and treatment of psychiatric disorders such as anxiety, depression and psychosis Deakin, 1988, Schmidt et al., 1995. There is a good correlation between hallucinogenic potency of drugs and their affinity for 5-HT2A receptors Glennon et al., 1984, Titeler et al., 1988. Furthermore, 5-HT2A antagonists block the psychotomimetic effects of hallucinogens in humans (Vollenweider et al., 1998). Therefore, it has been hypothesized that the 5-HT2A receptor in the frontal cortex may be the primary site of action of hallucinogens and may by critically involved in the actions of many atypical antipsychotics (Aghajanian and Marek, 1999). Electrophysiological studies in rat cortical slices demonstrated that serotonin, as well as hallucinogens lysergic acid diethylamide (LSD) and (±)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), induces a robust increase in spontaneous excitatory postsynaptic potentials (EPSPs) in layer V pyramidal neurons (Aghajanian and Marek, 1997). This effect is mediated via 5-HT2A receptors and may underlie the hallucinogenic action of 5-HT2A receptor agonists Abi-Saab et al., 1999, Aghajanian and Marek, 1999. In behavioral studies in rodents, 5-HT2A agonists induce head twitches, and this behaviour provides an experimental model to study 5-HT2 receptor function in the brain Green et al., 1983, Darmani et al., 1990.

There is growing evidence that interactions of excitatory amino acids (EAAs) and serotonin may be important for the control of many brain activities and play an important role in a wide range of behaviours Arvanov et al., 1999, Martin et al., 1998, Kim et al., 1999, Loscher and Honack, 1993, Płaźnik et al., 1994, Płaźnik et al., 1997. Electrophysiological studies have shown that serotonin exerts various modulatory effects on glutamatergic transmission, depending on the brain region studied and serotonin receptor subtype involved Marek and Aghajanian, 1998, Schmitz et al., 1998. On the other hand, glutamate, via stimulation of metabotropic glutamate (mGlu) receptors, can also modulate some effects of 5-HT receptor activation. Aghajanian and Marek (1997) have demonstrated that a nonselective mGlu receptor agonist, 1-Aminocyclopentane-1,3-dicarboxylic acid (ACPD), suppresses the increase in frequency of spontaneous EPSPs and excitatory postsynaptic currents (EPSCs) induced in rat cerebral cortex layer V pyramidal cells by 5-HT2A receptor activation. Recently, Marek et al. (1999) and Aghajanian and Marek (1999), using intracellular recording from layer V pyramidal cells in the rat medial prefrontal cortex, provided evidence that two selective Group II mGlu agonists, (+)-2-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid (LY354740) and (−)2-oxa-4-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid (LY379268), also suppressed the increase in EPSCs induced by 5-HT. Furthermore, the mGlu 2/3 antagonist, (2S,1′S,2′S)-2-(9-xantyhylmethyl)-2-(2′-carboxycyclopropyl)glycine (LY341495), blocked the suppressant effect of LY354740 on the 5-HT-induced EPSCs. LY341495 (by blocking mGlu2/3 receptors) was also able to enhance the frequency and amplitude of spontaneous EPSCs induced by 5-HT (through activation of the 5-HT2A receptor) (Marek et al., 1999), suggesting that endogenous glutamate released by activation of 5-HT2A receptors can activate presynaptic inhibitory Group II mGluR receptors. In parallel to these electrophysiological data, Gewirtz and Marek (2000) demonstrated that administration of LY354740 suppressed DOI-induced head twitches in rats.

In our experiments, we confirmed and extended those findings to mice. We investigated the action of potent and selective Group II mGlu receptor agonists LY354740 and LY379268 on DOI-induced head twitches in mice. Additionally, we studied the effect of LY379268 on DOI-induced spontaneous EPSPs using intracellular and patch-clamp recordings in layer V cortical cells in the mouse frontal cortex.

Section snippets

Animals and housing

The Animal Care and Use Committee at the Institute of Pharmacology approved all experimental procedures. The experiments were carried out on mice (male Albino-Swiss, 24–26 or 20 g for electrophysiology). The animals were kept at an ambient temperature of 20±1 °C and had free access to food (standard laboratory pellets) and tap water before the experiment.

Head twitch test

In order to habituate mice to the experimental environment, each animal was randomly transferred to a 12 cm (diameter)×20 cm (height) glass

DOI-induced head twitches

Ketanserin used as a positive control in our study, produced a dose-dependent decrease (by 90% after the highest dose) in the number of head twitches [F(3,32)=33,389, P<.01] (Fig. 1A). The Group II mGlu receptor agonists LY354740 (0.025–1 mg/kg) significantly [F(7,59)=10.152, P<.001] decreased DOI-induced head twitches (Fig. 1B). The maximal inhibition (by 64%) occurred after a dose of 0.1 mg/kg. The dose–response curve to LY354740 was bell-shaped so that the compound at a dose of 5 mg/kg was

Discussion

Recently discovered, selective, potent and systemically active agonists of Group II mGlu receptors show a wide variety of effects of possible clinical importance. It has been shown in animal studies that agonists of Group II mGlu receptors exhibit anxiolytic-like effects Helton et al., 1998, Kłodzińska et al., 1999, exhibit antiaddictive effects Helton et al., 1997, Kłodzińska et al., 1999, inhibit tolerance to analgesic effects of morphine (Popik et al., 2000), and possess antiseizure activity

Acknowledgements

The study was supported by the Institute of Pharmacology, Polish Academy of Sciences. The authors are grateful to Dr. D.D. Schoepp from Eli Lilly, Indianapolis, IN, for the generous gift of LY354740 and LY379268.

References (42)

  • W Loscher et al.

    Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats

    Eur J Pharmacol

    (1993)
  • OJ Manzoni et al.

    Pharmacology of metabotropic glutamate receptors at the mossy fiber synapses of the guinea pig hippocampus

    Neuropharmacology

    (1995)
  • GJ Marek et al.

    The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis

    Biol Psychiatry

    (1998)
  • A Płaźnik et al.

    The behavioral effects of NMDA antagonists in serotonin depleted rats

    Pharmacol, Biochem Behav

    (1997)
  • CJ Schmidt et al.

    The role of 5-HT2A receptors in antipsychotic activity

    Life Sci

    (1995)
  • DD Schoepp et al.

    Pharmacological agents acting at subtypes of metabotropic glutamate receptors

    Neuropharmacology

    (1999)
  • R Schreiber et al.

    LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine

    Eur J Pharmacol

    (2000)
  • A Ugolini et al.

    Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus

    Eur J Pharmacol

    (1995)
  • GK Aghajanian et al.

    Serotonin–glutamate interactions: a new target for antipsychotic drugs

    Neuropsychopharmacology

    (1999)
  • VL Arvanov et al.

    A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex

    Eur J Neurosci

    (1999)
  • J Cartmell et al.

    The metabotropic glutamate 2/3 receptor agonists drugs. LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats

    J Pharmacol Exp Ther

    (1999)
  • Cited by (91)

    • Serotonin and schizophrenia

      2020, Handbook of Behavioral Neuroscience
    View all citing articles on Scopus
    View full text